Compendia wins $2.4M for cancer project

Michigan-based Compendia Bioscience has won a $2.4 million SBIR Fast Track Award from the National Cancer Institute for Oncomine, a system that combines a rapidly growing compendium of over 20,000 cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application. Oncomine will be used for data mining and visualization, biomarker and therapeutic target discovery, validation, and prioritization.

"Over the past year we have seen ever increasing acceptance of Oncomine in the biopharmaceutical arena, and with that growing sales, marketing, and business development demands," commented CEO John Freshley. "I am looking forward to concentrating on the continued commercial adaptation of this important product."

- see this announcement from Compendia

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.